{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:50:04Z","timestamp":1768279804341,"version":"3.49.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["720694"],"award-info":[{"award-number":["720694"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40273-021-01081-y","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:12:23Z","timestamp":1630721543000},"page":"91-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-\u03b21a Therapy Versus Injectable Interferon-\u03b21a Treatment in Relapsing\u2013Remitting Multiple Sclerosis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1478-813X","authenticated-orcid":false,"given":"Laurenske A.","family":"Visser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3544-0554","authenticated-orcid":false,"given":"Marc","family":"Folcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-9311","authenticated-orcid":false,"given":"Claudia","family":"Delgado Simao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biotza","family":"Gutierrez Arechederra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Encarna","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-5203","authenticated-orcid":false,"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9538-4083","authenticated-orcid":false,"given":"William Ken","family":"Redekop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"issue":"3","key":"1081_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, et al. Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269\u201385. https:\/\/doi.org\/10.1016\/S1474-4422(18)30443-5.","journal-title":"Lancet Neurol"},{"issue":"10076","key":"1081_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0140-6736(16)30959-X","volume":"389","author":"WJ Brownlee","year":"2017","unstructured":"Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(16)30959-X.","journal-title":"Lancet"},{"issue":"May","key":"1081_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.msard.2018.07.013","volume":"25","author":"L Barin","year":"2018","unstructured":"Barin L, et al. The disease burden of multiple sclerosis from the individual and population perspective: which symptoms matter most? Mult Scler Relat Disord. 2018;25(May):112\u201321. https:\/\/doi.org\/10.1016\/j.msard.2018.07.013.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1081_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11136-005-0891-6","volume":"15","author":"A Miller","year":"2006","unstructured":"Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual Life Res. 2006;15(2):259\u201371. https:\/\/doi.org\/10.1007\/s11136-005-0891-6.","journal-title":"Qual Life Res"},{"key":"1081_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(96)00024-1","author":"BP Hermann","year":"1996","unstructured":"Hermann BP, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res. 1996. https:\/\/doi.org\/10.1016\/0920-1211(96)00024-1.","journal-title":"Epilepsy Res"},{"issue":"23","key":"1081_CR6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/09638280310001608591","volume":"25","author":"J Benito-Le\u00f3n","year":"2003","unstructured":"Benito-Le\u00f3n J, Manuel Morales J, Rivera-Navarro J, Mitchell AJ. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil. 2003;25(23):1291\u2013303. https:\/\/doi.org\/10.1080\/09638280310001608591.","journal-title":"Disabil Rehabil"},{"issue":"10076","key":"1081_CR7","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, S\u00f8rensen PS. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389(10076):1347\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(16)32388-1.","journal-title":"Lancet"},{"issue":"1","key":"1081_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s13311-015-0412-4","volume":"13","author":"J Ingwersen","year":"2016","unstructured":"Ingwersen J, Aktas O, Hartung HP. Advances in and algorithms for the treatment of relapsing\u2013remitting multiple sclerosis. Neurotherapeutics. 2016;13(1):47\u201357. https:\/\/doi.org\/10.1007\/s13311-015-0412-4.","journal-title":"Neurotherapeutics"},{"key":"1081_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101929","author":"LA Visser","year":"2020","unstructured":"Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2020. https:\/\/doi.org\/10.1016\/j.msard.2020.101929.","journal-title":"Mult Scler Relat Disord"},{"issue":"September 2017","key":"1081_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.msard.2017.11.013","volume":"19","author":"P Rieckmann","year":"2018","unstructured":"Rieckmann P, et al. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord. 2018;19(September 2017):153\u201360. https:\/\/doi.org\/10.1016\/j.msard.2017.11.013.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1081_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","volume":"30","author":"SC Steinberg","year":"2010","unstructured":"Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89\u2013100. https:\/\/doi.org\/10.2165\/11533330-000000000-00000.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1081_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pbj.2017.07.001","volume":"2","author":"F Michel","year":"2017","unstructured":"Michel F, Folcher M. Optogenerapy: when bio-electronic implant enters the modern syringe era. Porto Biomed J. 2017;2(5):145\u20139. https:\/\/doi.org\/10.1016\/j.pbj.2017.07.001.","journal-title":"Porto Biomed J"},{"key":"1081_CR13","unstructured":"Presas M, Martins L, Guitierrez B. D6.4. Public Communication Materials. H2020-NMBP-09-2016\/GA No. 720694. 2018. [Online]. https:\/\/optogenerapy.eu\/wp-content\/uploads\/2018\/10\/Optogenerapy_D6.4_PublicCommMaterials.pdf. Accessed 29 Dec 2019"},{"key":"1081_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-021-00561-z","author":"LA Visser","year":"2021","unstructured":"Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Health-related quality of life of multiple sclerosis patients: a European multi-country study. Arch Public Health. 2021. https:\/\/doi.org\/10.1186\/s13690-021-00561-z.","journal-title":"Arch Public Health"},{"issue":"11","key":"1081_CR15","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"key":"1081_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms6392","volume":"5","author":"M Folcher","year":"2014","unstructured":"Folcher M, et al. Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant. Nat Commun. 2014;5:1\u201311. https:\/\/doi.org\/10.1038\/ncomms6392.","journal-title":"Nat Commun"},{"key":"1081_CR17","unstructured":"CBO, \u201cRichtlijn Multiple Sclerose, 2012,\u201d Nederlandse Vereniging voor Neurologie, 2012. https:\/\/richtlijnendatabase.nl\/richtlijn\/multipele_sclerose\/multipele_sclerose_-_startpagina.html. Accessed 05 Nov 2019."},{"key":"1081_CR18","unstructured":"The Institute for Clinical and Economic Review (ICER). Disease-modifying therapies for relapsing remitting and primary-progressive multiple sclerosis: effectiveness and value. Final Evidence Report; 2017. p. 253."},{"issue":"3","key":"1081_CR19","doi-asserted-by":"publisher","first-page":"e0150703","DOI":"10.1371\/journal.pone.0150703","volume":"11","author":"J Chevalier","year":"2016","unstructured":"Chevalier J, Chamoux C, Hamm\u00e8s F, Chicoye A. Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: a French societal perspective. PLoS\u00a0One. 2016;11(3):e0150703. https:\/\/doi.org\/10.1371\/journal.pone.0150703.","journal-title":"PLoS\u00a0One"},{"issue":"7","key":"1081_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3111\/13696998.2016.1157080","volume":"19","author":"L Hernandez","year":"2016","unstructured":"Hernandez L, Guo S, Kinter E, Fay M. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. J Med Econ. 2016;19(7):684\u201395. https:\/\/doi.org\/10.3111\/13696998.2016.1157080.","journal-title":"J Med Econ"},{"key":"1081_CR21","unstructured":"Zorginstituut Nederland, \u201cRichtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg,\u201d Diemen, 2016."},{"issue":"2","key":"1081_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, et al. Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350. https:\/\/doi.org\/10.1016\/j.jval.2013.02.002.","journal-title":"Value Health"},{"issue":"4","key":"1081_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Ramos IC, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361. https:\/\/doi.org\/10.1007\/s40273-015-0327-2.","journal-title":"Pharmacoeconomics"},{"key":"1081_CR24","unstructured":"Mashayekhi M, Loi A, Freixas B, Gaucci P, Delgado C, Lacharmoise P. Bio-electronic cell based implant for multiple sclerosis protein therapy. 2018."},{"issue":"6","key":"1081_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/europace\/euv217","volume":"18","author":"TA Kanters","year":"2016","unstructured":"Kanters TA, et al. Cost comparison of two implantable cardiac monitors in two different settings: reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room. Europace. 2016;18(6):919\u201324. https:\/\/doi.org\/10.1093\/europace\/euv217.","journal-title":"Europace"},{"issue":"2_suppl","key":"1081_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1352458517708663","volume":"23","author":"B Uitdehaag","year":"2017","unstructured":"Uitdehaag B, Kobelt G, Berg J, Capsa D, Dalen J, The European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: results for the Netherlands. Mult Scler J. 2017;23(2_suppl):117\u201329. https:\/\/doi.org\/10.1177\/1352458517708663.","journal-title":"Mult Scler J"},{"key":"1081_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00144.x","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00144.x.","journal-title":"Value Health"},{"key":"1081_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-346","author":"S Acaster","year":"2013","unstructured":"Acaster S, Perard R, Chauhan D, Lloyd AJ. A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis. BMC Health Serv Res. 2013. https:\/\/doi.org\/10.1186\/1472-6963-13-346.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1081_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","volume":"28","author":"H Tan","year":"2011","unstructured":"Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51\u201361. https:\/\/doi.org\/10.1007\/s12325-010-0093-7.","journal-title":"Adv Ther"},{"issue":"2","key":"1081_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1399-5448.2009.00546.x","volume":"11","author":"SE Hofer","year":"2010","unstructured":"Hofer SE, et al. Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria. Pediatr Diabetes. 2010;11(2):116\u201321. https:\/\/doi.org\/10.1111\/j.1399-5448.2009.00546.x.","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"1081_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/1932296816663963","volume":"11","author":"JC Wong","year":"2017","unstructured":"Wong JC, et al. Evaluation of pump discontinuation and associated factors in the T1D Exchange Clinic Registry. J Diabetes Sci Technol. 2017;11(2):224\u201332. https:\/\/doi.org\/10.1177\/1932296816663963.","journal-title":"J Diabetes Sci Technol"},{"issue":"9","key":"1081_CR32","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.clinthera.2007.09.025","volume":"29","author":"SR Schwid","year":"2007","unstructured":"Schwid SR, Panitch HS. Full results of the evidence of interferon dose-response-European North American comparative efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon \u03b2-1a for relapsin. Clin Ther. 2007;29(9):2031\u201348. https:\/\/doi.org\/10.1016\/j.clinthera.2007.09.025.","journal-title":"Clin Ther"},{"issue":"1\u20132","key":"1081_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jns.2011.05.024","volume":"307","author":"GP Christophi","year":"2011","unstructured":"Christophi GP, et al. Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-\u03b2 1a treated multiple sclerosis patients. J Neurol Sci. 2011;307(1\u20132):41\u20135. https:\/\/doi.org\/10.1016\/j.jns.2011.05.024.","journal-title":"J Neurol Sci"},{"key":"1081_CR34","unstructured":"Zorginstituut Nederland, \u201cKosteneffectiviteit in de praktijk,\u201d 2015. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2015\/06\/26\/kosteneffectiviteit-in-de-praktijk. Accessed 12 Aug 2020."},{"issue":"9","key":"1081_CR35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40273-019-00810-8","volume":"37","author":"MM Versteegh","year":"2019","unstructured":"Versteegh MM, Ramos IC, Buyukkaramikli NC, Ansaripour A, Reckers-Droog VT, Brouwer WBF. Severity\u2014adjusted probability of being cost effective. Pharmacoeconomics. 2019;37(9):1155\u201363. https:\/\/doi.org\/10.1007\/s40273-019-00810-8.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1081_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40258-019-00500-8","volume":"17","author":"RE Michels","year":"2019","unstructured":"Michels RE, et al. Cost effectiveness of cladribine tablets for the treatment of relapsing\u2014remitting multiple sclerosis in The Netherlands. Appl Health Econ Health Policy. 2019;17(6):857\u201373. https:\/\/doi.org\/10.1007\/s40258-019-00500-8.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"1081_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1057\/palgrave.jcb.3050062","volume":"13","author":"E Cosh","year":"2007","unstructured":"Cosh E, Girling A, Lilford R, McAteer H, Young T. Investing in new medical technologies: a decision framework. J Commer Biotechnol. 2007;13(4):263\u201371. https:\/\/doi.org\/10.1057\/palgrave.jcb.3050062.","journal-title":"J Commer Biotechnol"},{"key":"1081_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.techfore.2016.07.041","volume":"112","author":"K Markiewicz","year":"2016","unstructured":"Markiewicz K, van Til JA, Steuten LMG, IJzerman MJ. Commercial viability of medical devices using Headroom and return on investment calculation. Technol Forecast Soc Change. 2016;112:338\u201346. https:\/\/doi.org\/10.1016\/j.techfore.2016.07.041.","journal-title":"Technol Forecast Soc Change"},{"key":"1081_CR39","unstructured":"Hakkaart-van Roijen L, Van Der Linden N, Bouwmans CAM, Kanters TA, Tan SS. \u201cKostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg,\u201d Diemen, 2015."},{"key":"1081_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","volume":"9","author":"E Fogarty","year":"2016","unstructured":"Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Mult Scler Relat Disord. 2016;9:23\u201330. https:\/\/doi.org\/10.1016\/j.msard.2016.06.001.","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"1081_CR41","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/jnnp-2018-318228","volume":"89","author":"J Chen","year":"2018","unstructured":"Chen J, Taylor BV, Blizzard L, Simpson S, Palmer AJ, van der Mei IAF. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. J Neurol Neurosurg Psychiatry. 2018;89(11):1200\u20137. https:\/\/doi.org\/10.1136\/jnnp-2018-318228.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1081_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40273-017-0577-2","volume":"36","author":"S Iannazzo","year":"2018","unstructured":"Iannazzo S, Iliza AC, Perrault L. Disease-modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies. Pharmacoeconomics. 2018;36(2):189\u2013204. https:\/\/doi.org\/10.1007\/s40273-017-0577-2.","journal-title":"Pharmacoeconomics"},{"issue":"1\u20132","key":"1081_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijpharm.2018.03.041","volume":"543","author":"A Ca\u00f1ibano-Hern\u00e1ndez","year":"2018","unstructured":"Ca\u00f1ibano-Hern\u00e1ndez A, S\u00e1enz del Burgo L, Espona-Noguera A, Ciriza J, Pedraz JL. Current advanced therapy cell-based medicinal products for type-1-diabetes treatment. Int J Pharm. 2018;543(1\u20132):107\u201320. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.03.041.","journal-title":"Int J Pharm"},{"issue":"March 2018","key":"1081_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.preteyeres.2018.10.002","volume":"68","author":"G Orive","year":"2019","unstructured":"Orive G, et al. 3D cell-laden polymers to release bioactive products in the eye. Prog Retin Eye Res. 2019;68(March 2018):67\u201382. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.10.002.","journal-title":"Prog Retin Eye Res"},{"issue":"February","key":"1081_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2019.00038","volume":"13","author":"S Mitra","year":"2019","unstructured":"Mitra S, Behbahani H, Eriksdotter M. Innovative therapy for Alzheimer\u2019s disease-with focus on biodelivery. Front Neurosci. 2019;13(February):1\u201321. https:\/\/doi.org\/10.3389\/fnins.2019.00038.","journal-title":"Front Neurosci"},{"issue":"7","key":"1081_CR46","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40273-017-0509-1","volume":"35","author":"MJ Ijzerman","year":"2017","unstructured":"Ijzerman MJ, Koffijberg H, Fenwick E, Krahn M. Emerging use of early health technology assessment in medical product development: a scoping review of the literature. Pharmacoeconomics. 2017;35(7):727\u201340. https:\/\/doi.org\/10.1007\/s40273-017-0509-1.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1081_CR47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.15171\/ijhpm.2017.11","volume":"6","author":"P Lehoux","year":"2017","unstructured":"Lehoux P, Miller FA, Daudelin G, Denis JL. Providing value to new health technology: the early contribution of entrepreneurs, investors, and regulatory agencies. Int J Health Policy Manag. 2017;6(9):509\u201318. https:\/\/doi.org\/10.15171\/ijhpm.2017.11.","journal-title":"Int J Health Policy Manag"},{"key":"1081_CR48","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/1352458516650743","volume":"22","author":"R Gold","year":"2016","unstructured":"Gold R, Toumi M, Meesen B, Fogarty E. The payer\u2019s perspective: what is the burden of MS and how should the patient\u2019s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment? Mult Scler. 2016;22:60\u201370. https:\/\/doi.org\/10.1177\/1352458516650743.","journal-title":"Mult Scler"},{"issue":"3","key":"1081_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40271-018-0305-9","volume":"11","author":"DJ Mott","year":"2018","unstructured":"Mott DJ. Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? Patient. 2018;11(3):249\u201352. https:\/\/doi.org\/10.1007\/s40271-018-0305-9.","journal-title":"Patient"},{"issue":"6","key":"1081_CR50","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","volume":"18","author":"C Bouwmans","year":"2015","unstructured":"Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Van Roijen LH. The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18(6):753\u20138. https:\/\/doi.org\/10.1016\/j.jval.2015.05.009.","journal-title":"Value Health"},{"key":"1081_CR51","unstructured":"Bouwmans C, Hakkaart-Van Roijen L, Koopmanschap M, Krol M, Severens H, Brouwer W. \u201ciMTA Medical Consumption Questionnaire Handleiding,\u201d Rotterdam; 2018. [Online]. www.imta.nl."},{"issue":"10","key":"1081_CR52","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s40273-018-0683-9","volume":"36","author":"L Hernandez","year":"2018","unstructured":"Hernandez L, O\u2019Donnell M, Postma M. Modeling approaches in cost-effectiveness analysis of disease-modifying therapies for relapsing\u2013remitting multiple sclerosis: an updated systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36(10):1223\u201352. https:\/\/doi.org\/10.1007\/s40273-018-0683-9.","journal-title":"Pharmacoeconomics"},{"key":"1081_CR53","unstructured":"MDIC, \u201cMedical Device Innovation Consortium (MDIC): Patient Centered Risk-Benefit Project Report.\u201d Med. Device Innov. Consort., no. MDIC; 2015. p. 151."},{"key":"1081_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2020.07.007","author":"C Whichello","year":"2020","unstructured":"Whichello C, et al. An overview of critical decision-points in the medical product lifecyle: where to include patient preference information in the decision-making process? Health Policy (New York). 2020. https:\/\/doi.org\/10.1016\/j.healthpol.2020.07.007.","journal-title":"Health Policy (New York)"},{"issue":"1","key":"1081_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40263-014-0207-x","volume":"29","author":"X Zhang","year":"2015","unstructured":"Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-\u03b21a in relapsing-remitting multiple sclerosis. CNS Drugs. 2015;29(1):71\u201381. https:\/\/doi.org\/10.1007\/s40263-014-0207-x.","journal-title":"CNS Drugs"},{"issue":"3","key":"1081_CR56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/13696998.2016.1258366","volume":"20","author":"D Bozkaya","year":"2017","unstructured":"Bozkaya D, Livingston T, Migliaccio-Walle K, Odom T. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2017;20(3):297\u2013302. https:\/\/doi.org\/10.1080\/13696998.2016.1258366.","journal-title":"J Med Econ"},{"key":"1081_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.028","author":"E Soini","year":"2017","unstructured":"Soini E, Joutseno J, Sumelahti ML. Cost-utility of first-line disease-modifying treatments for relapsing-remitting multiple sclerosis. Clin Ther. 2017. https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.028.","journal-title":"Clin Ther"},{"key":"1081_CR58","unstructured":"Zorginstituut, \u201cZorginstituut Nederland.\u201d https:\/\/www.medicijnkosten.nl\/. Accessed 01 Nov 2019."},{"key":"1081_CR59","unstructured":"Star-shl, \u201cStar-shl,\u201d 2019."},{"issue":"6","key":"1081_CR60","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10198-019-01036-3","volume":"20","author":"LS Matza","year":"2019","unstructured":"Matza LS, et al. Health state utilities associated with post-surgical Staphylococcus aureus infections. Eur J Health Econ. 2019;20(6):819\u201327. https:\/\/doi.org\/10.1007\/s10198-019-01036-3.","journal-title":"Eur J Health Econ"},{"issue":"9","key":"1081_CR61","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s10198-014-0649-6","volume":"16","author":"LS Matza","year":"2015","unstructured":"Matza LS, et al. Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ. 2015;16(9):1005\u201318. https:\/\/doi.org\/10.1007\/s10198-014-0649-6.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"1081_CR62","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"P Sullivan","year":"2006","unstructured":"Sullivan P, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006;26(4):410\u201320. https:\/\/doi.org\/10.1177\/0272989X06290495.","journal-title":"Med Decis Mak"},{"issue":"9","key":"1081_CR63","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s11136-019-02163-3","volume":"28","author":"LS Matza","year":"2019","unstructured":"Matza LS, Deger KA, Vo P, Maniyar F, Goadsby PJ. Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. Qual Life Res. 2019;28(9):2359\u201372. https:\/\/doi.org\/10.1007\/s11136-019-02163-3.","journal-title":"Qual Life Res"},{"issue":"3","key":"1081_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","volume":"12","author":"KS Boye","year":"2011","unstructured":"Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219\u201330. https:\/\/doi.org\/10.1007\/s10198-010-0224-8.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"1081_CR65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"2005","unstructured":"Jacobs LD, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 2005;39(3):285\u201394. https:\/\/doi.org\/10.1002\/ana.410390304.","journal-title":"Ann Neurol"},{"key":"1081_CR66","unstructured":"Haas J et al., Fingolimod reduces the number of severe relapses in patients with relapsing multiple sclerosis: results from phase III TRANSFORMS and FREEDOMS studies. 2011. researchgate.net\/profile\/Philipp_Von_Rosenstiel2\/publication\/266155869_Fingolimod_reduces_the_number_of_severe_relapses_in_patients_with_relapsing_multiple_sclerosis_Results_from_phase_III_TRANSFORMS_and_FREEDOMS_studies\/links\/543fafab0cf21227a11a9889.pdf. Accessed 19 Mar 2020."},{"issue":"4","key":"1081_CR67","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3171\/2009.5.SPINE08633","volume":"11","author":"JE O\u2019Toole","year":"2009","unstructured":"O\u2019Toole JE, Eichholz KM, Fessler RG. Surgical site infection rates after minimally invasive spinal surgery: clinical article. J Neurosurg Spine. 2009;11(4):471\u20136. https:\/\/doi.org\/10.3171\/2009.5.SPINE08633.","journal-title":"J Neurosurg Spine"},{"issue":"7","key":"1081_CR68","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/1352458511433302","volume":"18","author":"G Giovannoni","year":"2012","unstructured":"Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler J. 2012;18(7):932\u201346. https:\/\/doi.org\/10.1177\/1352458511433302.","journal-title":"Mult Scler J"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01081-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T21:44:49Z","timestamp":1641505489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01081-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01081-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,4]]},"assertion":[{"value":"10 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project has received funding from the European Union's Horizon 2020 research and innovation program under Grant agreement No 720694.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"L.A. Visser has no conflicts of interests to declare. M. Folcher has no conflicts of interests to declare. C. Delgado Simao has no conflicts of interests to declare. B. Gutierrez Arechederra has no conflicts of interests to declare. E. Encarna has no conflicts of interests to declare. C.A. Uyl-de Groot has no conflicts of interests to declare. W.K. Redekop has no conflicts of interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"The code that supports the findings of this study is available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"Conceptualization: LAV, WKR. Methodology: LAV, WKR. Formal analysis and investigation: LAV. Writing original draft preparation: LAV. Writing review and editing: MF, CDS, BGA, EE, CAUdG, WKR. Funding acquisition: MF, BGA, WKR. Supervision: CAUdG, WKR.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}